Biotie makes changes to management team

Appoints new Chief Executive, Chief Financial Officer and Chief Medical Officer

Timo Veromaa, President and CEO of Biotie Therapies, David Cook, CFO and Stephen Bandak, CMO are leaving the company today (30 June).

The Board of Directors of the Finland-based biopharmaceutical firm has appointed Antero Kallio, as the new CEO and Kristian Rantala as CFO, effective 1 July.

Kallio is currently the Site Head of Biotie's operations in Turku, Finland and Kristian Rantala is Vice President Finance.

The responsibilities of the Chief Medical Officer will be divided among the company's research and development team staff members as well as with Acorda Therapeutics' interim Chief Medical Officer Burkard Blank.

Veromaa was appointed President and CEO of Biotie in 2005. He has led the company through a number of pivotal transactions, including financial restructurings, acquisition of Synosia Therapeutics in 2011 and IPO of Biotie in the US in 2015.

'We wish Timo, David and Stephen the best in their future endeavours,' said Ron Cohen, Chairman of the Board of Directors of Biotie.

You may also like

Research & Development

Michael J Fox Foundation to finance Parkinson\'s trials for Biotie Therapies and Cynapsus Therapeutics

Biotie will receive US$2m, while Cynapsus grant is $500,000
Research & Development

Biotie terminates agreement to buy Newron

Newron is exploring all options for safinamide
Finance

Biotie Therapies to acquire Newron for €45m

Will continue to focus on CNS drug development
Research & Development

Biotie to acquire Synosia in all-share deal

Will create a CNS drug development company
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Subscribe now